Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Consensus Rating of “Hold” from Brokerages

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) has received a consensus recommendation of “Hold” from the seven brokerages that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $12.80.

A number of equities analysts recently weighed in on XERS shares. Barclays lifted their target price on shares of Xeris Biopharma from $9.00 to $12.00 and gave the stock an “overweight” rating in a research note on Thursday, August 20th. Weiss Ratings downgraded Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Wall Street Zen raised Xeris Biopharma from a “hold” rating to a “buy” rating in a research report on Saturday, September 19th. Finally, Leerink Partners boosted their price objective on Xeris Biopharma from $12.00 to $16.00 and gave the company an “outperform” rating in a research note on Thursday, September 10th.

Xeris Biopharma Price Performance

Xeris Biopharma stock opened at $9.10 on Monday. The firm has a market cap of $1.66 billion, a PE ratio of -82.73 and a beta of 0.70. The stock’s fifty day moving average price is $8.36 and its two-hundred day moving average price is $7.17. Xeris Biopharma has a one year low of $5.25 and a one year high of $10.08. The company has a debt-to-equity ratio of 17.00, a current ratio of 1.45 and a quick ratio of 1.02.

Xeris Biopharma (NASDAQ:XERS) last issued its earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. The company had revenue of $92.10 million during the quarter, compared to analyst estimates of $90.12 million. As a group, research analysts expect that Xeris Biopharma will post 0.07 EPS for the current fiscal year.

Insider Transactions at Xeris Biopharma

In other Xeris Biopharma news, insider Steven Pieper sold 27,600 shares of the firm’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $8.52, for a total value of $235,152.00. Following the transaction, the insider directly owned 1,366,053 shares of the company’s stock, valued at approximately $11,638,771.56. This trade represents a 1.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Beth Hecht sold 16,666 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $8.49, for a total transaction of $141,494.34. Following the completion of the transaction, the insider directly owned 1,127,796 shares in the company, valued at approximately $9,574,988.04. The trade was a 1.46% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 224,998 shares of company stock valued at $1,847,219 in the last 90 days. 4.35% of the stock is currently owned by corporate insiders.

Institutional Trading of Xeris Biopharma

Several institutional investors and hedge funds have recently modified their holdings of XERS. Allworth Financial LP purchased a new position in shares of Xeris Biopharma during the second quarter valued at approximately $34,000. KBC Group NV bought a new position in Xeris Biopharma during the 1st quarter valued at $27,000. State of Wyoming bought a new position in Xeris Biopharma during the 2nd quarter valued at $52,000. Integrated Wealth Concepts LLC purchased a new position in Xeris Biopharma during the 2nd quarter worth $74,000. Finally, Kingsview Wealth Management LLC bought a new stake in shares of Xeris Biopharma in the 4th quarter worth $78,000. 42.75% of the stock is owned by hedge funds and other institutional investors.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc (NASDAQ:XERS) is a specialty pharmaceutical company focused on developing and commercializing therapies using proprietary formulation and drug-delivery technologies. Its platforms, including XeriSol and XeriJect, are designed to enable liquid or ready-to-use formulations of medicines that may otherwise require refrigeration, reconstitution, or administration by a healthcare professional.

The company’s commercial products include Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia; Keveyis (dichlorphenamide), an oral therapy for primary periodic paralysis; and Recorlev (levoketoconazole), an oral treatment for endogenous hypercortisolemia in adults with Cushing’s syndrome.